Washington: This is indeed a wake-up call to the food and drug watchdog, The FDA, to spruce up its scrutiny of prevailing medicines in the market. This has been put forth vociferously by Editors of a medical journal and members of a drug-safety advisory panel.
A report enabled by The Institute of Medicine (IOM) has beseeched the U.S. Congress to equip the FDA with more manpower, finance and authority to be able to conduct post-approval research of drugs as well as alter labels and warnings appropriately.
While petitioning for an end to the politicization of the FDA, the editors said in a statement, "We face a mounting public health crisis in drug safety, and definitive action must be taken. The IOM committee's report is a crucial starting point."
Underlining the FDA's lack of proactive action in the matter of Vioxx, a drug by the Merck & Co Inc, which was in a soup following an association to heart damage, critics have come down strongly regarding the former's response to the drug's associated problems and about other medicines available in the market.
FDA officials have reiterated that they are taking adequate steps to improve the drug safety norms and are soaking in the suggestions of the IOM report.